On November 24, 2025, Novartis AG announced FDA approval for Itvisma®, the first gene replacement therapy for spinal muscular atrophy (SMA), providing a one-time treatment option for patients aged two and older. This approval marks a significant advancement in SMA care as Itvisma can improve motor function with a one-time injection, reducing the need for chronic treatments.